NCCN survey reveals ongoing shortages in crucial cancer medications

FHS
June 26, 2024
6:41 pm

The National Comprehensive Cancer Network (NCCN)-;a nonprofit alliance of leading cancer centers-;is publishing new results for its latest survey on cancer drug shortages in the United States.

At Third Arc Bio, former J&J leaders raise $165M to test oncology, autoimmune biologics

Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS

July 24, 2024

The Psychedelic Drug Development Pipeline: Bullseye Chart Year-End 2023 – Psychedelic Alpha

In early 2023, we visualised our Psychedelics Drug Development Tracker data in a ‘bullseye chart’ format as part of 2022’s Year in Review. Due to its

February 6, 2024

BMS licenses TCR-T immunotherapy therapy from Immatics – Pharmaceutical Technology

Headquarters of Bristol-Myers Squibb (BMS) Germany in Munich, Germany. BMS has exercised opt-in rights for a new TCR-T therapy from Immatics. Credit: Shutterstock/nitpicker Bristol Myers

May 2, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.